Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical combination containing rapamycin for treating large intestine cancer

A technology of rapamycin and composition, which is applied in the field of pharmaceutical composition for treating colorectal cancer, can solve problems such as unsatisfactory effects, and achieve the effect of inhibiting the growth of human colorectal cancer cells

Inactive Publication Date: 2008-10-29
RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The purpose of the present invention is to provide a pharmaceutical composition containing rapamycin for the treatment of colorectal cancer, said pharmaceutical composition containing rapamycin for the treatment of colorectal cancer will solve the problems in the prior art Technical problem of unsatisfactory effect of pharmaceutical composition for treating colorectal cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical combination containing rapamycin for treating large intestine cancer
  • Pharmaceutical combination containing rapamycin for treating large intestine cancer
  • Pharmaceutical combination containing rapamycin for treating large intestine cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1 Cell Culture

[0053]The culture medium of SW480 cells (purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, SIBC) was RPMI-1640 complete culture medium (10% fetal bovine serum, 100U / ml penicillin / streptomycin), HT29 and HCT116 cells ( The medium purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (SIBC) was McCOY'S 5A MEDIUM (Sigma, USA) complete culture solution (10% fetal bovine serum, 100U / ml penicillin / streptomycin), and the three The culture conditions were 95% air, 5% CO 2 , 95% humidity, 37 ℃ constant temperature.

Embodiment 2

[0054] Embodiment 2MTT colorimetric experiment

[0055] Dilute the single cell suspension to 3×10 4 / ml, inoculated into 96-well culture plate at 100 μl / well. After culturing for 24 hours, when the cells were in the logarithmic growth phase, the original culture solution was discarded, and the working solution of each group of intervention drugs was added, and the following drug intervention groups were respectively set up:

[0056] RPM 10nmol / L

[0057] PD98059 10μmol / L

[0058] PD98059 10μmol / L+RPM 10nmol / L (the mass ratio of PD98059 to RPM is 292.4:1)

[0059] PD98059 20μmol / L

[0060] PD98059 20μmol / L+RPM 10nmol / L (the mass ratio of PD98059 to RPM is 584.8:1)

[0061] PD98059 40μmol / L

[0062] PD98059 40μmol / L+RPM 10nmol / L (the mass ratio of PD98059 to RPM is 1169.6:1)

[0063] PD98059 50μmol / L

[0064] PD98059 50 μmol / L+RPM 10 nmol / L (the mass ratio of PD98059 and RPM is 1462:1) to the control group, complete culture medium, 0.5% PBS, and 0.5% dimethyl sulfoxide (...

Embodiment 3

[0071] Example 3 Cell cycle detection

[0072] Cells in logarithmic growth phase were cultured in serum-free medium for 24 hours to synchronize them. The culture medium was changed to contain different drugs (RPM 10nmol / L, PD9805950μmol / L, RPM 10nmol / L+PD9805950μmol / L, in the combined action group of PD98059 and rapamycin, the mass ratio of PD98059 to rapamycin was 1462: 1) complete culture solution, continue to cultivate for 48h. Digest and collect cells with 0.25% trypsin, wash with PBS, fix with absolute ethanol at 4°C, and make about 10 6 The single cell suspension per ml was incubated with Tris-HCL buffer (pH7.4) containing 1% RNase for 10 min, stained with propidium iodide (PI), and detected by flow cytometry. The percentage of cells in each cycle was fitted according to the distribution of cells with relative different DNA contents. Eight samples were retested in each group, and the test was repeated three times, and the results were expressed as x±SD. The results a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug composite containing rapamycin for curing colorectal cancer. The drug composite is composed of PD98059 (2-amino-4-iso-oxygen flavone) and the rapamycin, the weight proportion of which is 292.4:1-1462:1. The invention can down regulate mTOR of colorectal cancer cells and the protein phosphorylation level of downstream p70s6K and 4E-BP1, so as to inhibit the proliferation activity of the colorectal cancer cells and simultaneously to block the growth cycle of the colorectal cancer cells, and then to inhibit the growth of human colorectal cancer cells and to reduce the incidence rate of the colorectal cancer and the tumor size in rats.

Description

Technical field: [0001] The invention relates to the chemical field, in particular to a composition, especially a pharmaceutical composition containing rapamycin for treating colorectal cancer. Background technique: [0002] In the prior art, the effects of the pharmaceutical compositions used for treating colorectal cancer are not ideal. Invention content: [0003] The purpose of the present invention is to provide a pharmaceutical composition containing rapamycin for the treatment of colorectal cancer, said pharmaceutical composition containing rapamycin for the treatment of colorectal cancer will solve the problems in the prior art The technical problem that the action of the pharmaceutical composition for treating colorectal cancer is unsatisfactory. [0004] The invention is a pharmaceutical composition containing rapamycin for treating colorectal cancer, which is characterized in that: the pharmaceutical composition is composed of 2-amino-4-isooxyflavone and rapamyc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/436A61P35/00A61K31/352
Inventor 房静远张燕捷
Owner RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com